Page last updated: 2024-08-23

paclitaxel and Melanoma

paclitaxel has been researched along with Melanoma in 255 studies

Research

Studies (255)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.39)18.7374
1990's29 (11.37)18.2507
2000's58 (22.75)29.6817
2010's123 (48.24)24.3611
2020's44 (17.25)2.80

Authors

AuthorsStudies
Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z1
Baasner, S; Beckers, T; Böhmer, FD; Burger, AM; Bürgermeister, J; Fiebig, HH; Frieser, M; Hockemeyer, J; Hufsky, H; Lyssenko, A; Mahboobi, S; Paper, DH; Pongratz, H1
Chai, H; Cordell, GA; Farnsworth, NR; Hollingshead, MG; Kardono, LB; Kinghorn, AD; Lantvit, D; Lee, IS; Mayo, JG; Mi, Q; Ngassapa, O; Peraza-Sánchez, S; Pezzuto, JM; Reyes-Lim, E; Riswan, S; Zhao, W1
Ayral-Kaloustian, S; Beyer, C; Discafani, C; Greenberger, L; Loganzo, F; Niu, C; Smith, D; Zask, A1
Ahn, S; Chen, J; Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, J1
Cichewicz, RH; Du, L; King, JB; Mooberry, SL; Robles, AJ1
Arnst, KE; Banerjee, S; Deng, S; Kumar, G; Li, GB; Li, W; Miller, DD; Wang, Y; White, SW; Yang, J; Yang, L1
Arnst, KE; Chen, ZS; Lei, ZN; Li, W; Ma, D; Miller, DD; Wang, Q; Xue, Y1
Arnst, KE; Chen, H; Kumar, G; Li, W; Ma, D; Miller, DD; Wang, Q; Wang, Y; White, SW; Wu, Z; Yang, J1
Gao, R; Li, N; Li, X; Ma, L; Mu, L; Song, W; Sun, Y; Tang, Z; Wang, N; Wang, R; Wei, M; Yang, C; Yang, G; Yu, X; Zhang, K; Zhang, Y; Zheng, N1
Hiura, A; Maeda, T; Nakagawa, T; Toyoshima, R; Uehara, J; Yoshino, K1
Bēma, D; Bērziņš, J; Buiķis, I; Freivalds, T; Harju, L; Miķelsone, I; Patetko, L; Simsone, Z1
Alimoradi, H; Baird, SK; Barzegar-Fallah, A; Dunlop, JL; Torbati, E1
Ewert, KK; Fisher, WS; Roberts, L; Safinya, CR; Tchounwou, C; Wei, S1
Adhav, R; An, T; Chan, UI; Deng, CX; Lei, JH; Li, J; Liu, J; Miao, K; Mo, L; Shu, X; Su, SM; Wang, Y; Xu, J; Xu, X; Zhang, X1
Ghanadian, M; Lanzotti, V; Mehdifar, P; Mirian, M; Yazdiniapour, Z; Zolfaghari, B1
Hu, Y; Ji, Z; Li, M; Wang, H; Xu, B; Xu, J; Yang, Y1
Duan, X; Gu, Z; Li, A; Lou, X; Pan, L; Qin, Z; Wan, J; Wang, F; Wang, M; Yao, X; Zhang, L; Zhu, L1
An, X; Chen, S; Dong, S; Guo, C; Li, X; Li, Y; Liu, C; Shen, N; Song, M; Zhang, W1
Akbari, V; Emami, J; Hejazi, E; Lavasanifar, A; Minaiyan, M; Rezazadeh, M1
Lan, M; Li, AA; Li, F; Xie, D; Yan, MY; Zhang, Y1
Dehdari Vais, R; Perota, G; Sattarahmady, N; Zahraie, N1
Feng, N; Guo, J; He, Y; He, Z; Hou, X; Hu, H; Jing, Q; Li, Y; Li, Z; Ruan, S; Wang, Z; Wu, T; Xia, Q; Zhang, B; Zhang, Y1
Bariwal, J; Bhattarai, RS; Deng, S; Hao, C; Kumar, V; Li, W; Mahato, RI1
Bąk, W; Bargieł, J; Cabaj, J; Góralczyk, A; Grabarska, A; Wróblewska-Łuczka, P; Łuszczki, JJ1
Lan, S; Wu, D; Zhang, Y1
Adrianzen, L; Chiu, YM; Keck, M; Lodhi, N; Nagpal, P; Parvez, Z; Sarojini, S; Suh, KS1
Cadoná, FC; D'Ávila, CMDS; Krause, LMF; Mello, GH; Viana, AR1
Banerjee, R; Jinka, S; Mondal, SK; Shankar, G; Srinivas, R1
Chan, TH; Chow, LMC; Kan, JWY; Liu, Z; Su, X; Wong, ILK; Yan, CSW1
Banerjee, S; Chen, H; Deng, S; Hartman, KL; Li, W; Meibohm, B; Miller, DD; Parmar, K; Pochampally, S; Wang, Y; White, SW; Wu, Z; Yun, MK1
Guan, E; Hu, Y; Ji, Z; Lin, B; Wang, H; Zhou, M1
Dai, J; Fu, S; Li, J; Liu, Y; Lu, Y; Ma, W; Shi, H; Wen, Q; Zhao, L; Zhou, P1
Ageev, E; Antuganov, D; Karpov, TE; Maistrenko, DN; Muslimov, AR; Peltek, OO; Petrov, A; Postovalova, A; Rogova, A; Stanzhevsky, AA; Timin, AS; Zuev, D; Zyuzin, MV1
Cho, H; Haque, TN; Rahman, S; Saraswat, AL; Sugandhi, VV; Xin, X1
Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ1
Adlsadabad, SY; Pourbadiei, B; Pourjavadi, A; Rahbariasr, N1
Ambriović-Ristov, A; Coopmans, K; Humphries, JD; Humphries, MJ; Lončarić, M; Majhen, D; Rac-Justament, A; Stojanović, N1
Dülgar, Ö; Elleson, KM; Markowitz, J; Saha, A1
Edwards, CRW; Goff, PS; Gorelkin, PV; Korchev, Y; Sviderskaya, EV; Woodcock, E; Zhang, Y1
Jin, B; Kim, SY; Lee, WW; Li, Q; Nam, A; Park, HJ; Ryu, MO; Son, MH; Song, WJ; Yang, JI; Youn, HY1
Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM1
Anderson, DM; Erickson, LA; Ernstoff, M; Javed, A; Markovic, SN; Reid, JM; Suman, VJ; Wall, DJ1
Gao, Z; Si, X; Xu, F; Zheng, Y1
Chen, X; Fu, Y; Gong, T; Hu, Y; Wang, M; Yu, R; Zhang, ZR1
Gong, T; He, Q; Huang, S; Lin, Q; Liu, W; Sun, X; Wang, L; Xiao, L; Zhang, L; Zhang, Y; Zhang, Z1
Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X1
Gebhardt, C; Gries, M; Holland-Letz, T; Mun, DH; Reinhard, R; Simon, SCS; Umansky, V; Utikal, J; Weber, R1
Bai, X; Chi, Z; Cui, C; Dai, J; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X; Yao, H; Zhou, L1
Lee, Y; Park, D1
Berges, A; Cho, H; Dean, E; Hong, JY; Irurzun-Arana, I; Kang, WK; Kim, KM; Kim, ST; Kozarewa, I; Lee, J; Lim, HY; Loembé, AB; Mortimer, P; Park, JO; Park, SH; Park, YS; Pierce, AJ; Smith, C; Smith, SA; Willis, S1
Ashworth, A1
Dingv, Y; Huang, FX; Jiang, H; Li, DD; Li, JJ; Liu, X; Wang, JH; Wen, XZ; Zhang, XS; Zhao, JJ1
Acri, T; Alhaj-Suliman, SO; Ebeid, K; Mekkawy, AI; Naguib, YW; Salem, AK; Wafa, EI1
Lee, BJ; Tran, PH; Tran, TT; Yoon, TJ1
Jeoung, D; Kim, Y; Yeon, M1
Carvalho, VFM; Costa-Lotufo, LV; de Lemos, DP; Giacone, DV; Lopes, LB; Maria-Engler, SS; Migotto, A; Zanoni, TB1
Bauer-Pohl, V; Bennett, K; Beqiri, M; Chen, G; Choi, H; Czerniecki, BJ; Damle, M; Davies, MA; Dunagin, M; Ellingsworth, C; Flaherty, K; Frederick, DT; Fukunaga-Kalabis, M; Garg, K; Gavin, BJ; Grinman, L; Griss, J; Gross, L; Hafner, C; Hards, R; Herlyn, D; Herlyn, M; Hristova, D; Hudgens, C; Jalili, A; Karanikas, G; Koller, J; Krepler, C; Lang, R; Liu, Q; Long, GV; Maurer, M; Mayerhöfer, M; Perego, M; Raj, A; Rappersberger, K; Schaider, H; Scholler, N; Schuchter, L; Scolyer, RA; Somasundaram, R; Tetzlaff, M; Tian, T; Wagner, C; Wagner, SN; Wargo, J; Watson, I; Wei, Z; Weihsengruber, F; Wu, L; Xu, X; Zhang, G; Zhang, J1
Allred, JB; Bryce, AH; Dronca, RS; Erickson, LA; Joseph, RW; Katipamula, R; King, DM; Kottschade, LA; Leitch, JM; Markovic, SN; McWilliams, RR; Rumilla, KM; Slostad, JA1
Chantharasamee, J; Ithimakin, S; Singsuksawat, E; Sootichote, R; Thuwajit, C; Thuwajit, P; Warnnissorn, M; Yenchitsomanus, PT1
Dukhanin, AS; Dukhanina, EA; Georgieva, SG; Luk'yanova, TI1
Adjei, AA; Bindeman, WE; Cao, S; Chanana, P; Dong, H; Dronca, RS; Harrington, SM; Jang, JS; Jen, J; Li, Y; Liu, X; Mansfield, AS; Markovic, SN; Park, SS; Yan, Y1
Han, T; Hao, J; Liu, J; Tang, H; Wang, M; Wang, X; Wang, Y; Zhuang, Q1
El-Masry, M; Fruehauf, JP; Jakowatz, JG; Osann, K; Parmakhtiar, B; Yamamoto, M1
Berić Jozić, G; Lukić, B; Marijanović, I; Miletić, D; Puljić Ćuk, A; Tica Sedlar, I; Tomić, K1
Chmielowski, B; Copley-Merriman, C; Liu, FX; Mauskopf, J; Stevinson, K; Wang, J; Zimovetz, EA1
He, Q; Li, M; Liu, J; Rao, J; Tang, X; Wan, D; Wang, X; Wang, Y; Wei, J; Xia, C; Yin, S; Zhang, Z1
Eshita, Y; Ji, RC; Kobayashi, T; Kubota, N; Mizuno, M; Onishi, M; Onishi, Y; Yoshida, J1
He, B; Jiang, T; Li, T; Ma, Y; Mo, R; Shen, S; Wang, T1
Forschner, A; Garbe, C; Gutmann, V; Kosnopfel, C; Makino, E; Niessner, H; Schittek, B; Sinnberg, T1
Corrie, P; Danson, S; Goff, M; Love, SB; Marshall, E; Mauch, C; Middleton, MR; Mohammed, SB; Plummer, E; Schadendorf, D; Scudder, C; Urbonas, V; Wheater, M; Zimmer, L1
Han, B; Sun, B; Wang, YB1
Hata, H; Hiura, A; Kato, M; Maeda, T; Nagai, K; Oaku, S; Yoshino, K1
Specenier, P1
Kirkwood, JM; Massa, RC1
Chan, J; Corrie, P; di Pietro, M; Fitzgerald, RC; Januszewicz, W; Liu, H1
Chowdhury, MR; Goto, M; Kamiya, N; Moniruzzaman, M; Moshikur, RM; Tahara, Y; Wakabayashi, R1
Chi, Z; Cui, C; Dai, J; Guo, J; Kong, Y; Ma, M; Sheng, X; Si, L; Tang, H; Xu, L; Xu, T; Yan, J; Yang, L; Yu, H; Yu, S1
Curran, C; Liang, G; Mehaidli, A; Nguyen, C; Pandey, S; Parashar, K; Pignanelli, C; Sood, S; Vegh, C; Wang, Y; Wu, J1
al-Ramadi, BK; Bashir, G; El-Kharrag, R; El-Taji, H; Fernandez-Cabezudo, MJ; George, JA; Torab, F1
Chang, W; Choi, MK; Hong, JY; Jung, HA; Kim, S; Kim, YS; Lee, J; Lee, SJ; Maeng, CH; Park, S1
Cliby, WA; Janco, JM; Markovic, SN; Weaver, AL1
Akasaka, T; Inoue, T; Kasai, S; Maesawa, C; Masuda, T; Shibazaki, M; Takahashi, K; Watanabe, A; Yasuhira, S1
Liu, YP; Luo, YH; Song, JG; Sun, P; Xu, HM; Zhang, L; Zhang, XJ1
Arrowsmith, ER; Hainsworth, JD; Hauke, RJ; Infante, JR; Rubin, MS; Shih, KC1
Carrà, A; D'Incalci, M; Davoli, E; Giavazzi, R; Morosi, L; Pretto, F; Spinelli, P; Zucchetti, M1
Costa, VM; Diniz, C; Fresco, P; Soares, AS3
El-Khattouti, A; Gomez, CR; Haïkel, Y; Hassan, M; Megahed, M; Selimovic, D1
Deng, R; Dong, L; Liang, R; Liu, S; Sullivan, M; Tao, J; Wang, J; Wang, K; Wu, M; Wu, X; Yang, X; Zhu, J1
Glowala-Kosinska, M; Gogler-Piglowska, A; Toma, A; Vydra, N; Widlak, W1
Ashida, A; Okuyama, R; Sato, Y; Uhara, H1
Amaravadi, RK; Anderson, AR; Fedorenko, IV; Gibney, GT; Kim, E; Kudchadkar, RR; Maria-Engler, SS; Massaro, RR; Messina, JL; Rebecca, VW; Smalley, KS; Sondak, VK1
Amonkar, MM; Casey, M; Demidov, LV; Dummer, R; Garbe, C; Grotzinger, K; Hassel, JC; Lefeuvre-Plesse, C; Milhem, M; Mohr, P; Patel, K; Robert, C; Rutkowski, P; Rutten, A; Schadendorf, D; Sherman, L; Steven, N; Trefzer, U; Ullenhag, G; Wolter, P; Wu, FS1
Koon, HB; Megahed, AI1
Arance, A; Conti, I; Garbe, C; Grob, JJ; Hahka-Kemppinen, M; Hamid, O; Hauschild, A; Hutson, TE; Ilaria, R; Kaiser, C; Lee, J; Lorigan, P; Maio, M; Mohr, P; Turner, PK; Wolter, P1
D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F1
Kato, J; Namikawa, K; Tanaka, R; Tsutsumida, A; Yamazaki, N1
Du, R; Song, P; Song, WD; Tang, YQ; Wang, C; Zhang, Q; Zhang, WQ; Zhang, X; Zhao, Y; Zhong, T1
Azzarito, T; Cesolini, A; Fais, S; Venturi, G1
Amemiya, H; Ando, N; Harada, K; Hosomura, N; Inozume, T; Kawamura, T; Matsuzawa, M; Shibagaki, N; Shimada, S1
Ciria, C; Collins, L; Corrie, P; Coupe, N; Gore, M; Gupta, A; Hategan, M; Larkin, J; Love, S; Middleton, MR; Suter, S; Wise, A1
Boasberg, P; Cruickshank, S; Hamid, O; Mesko, S; O'Day, S; Spitler, LE; Weber, RW1
Azzariti, A; Cocco, T; Ferretta, A; Guida, G; Guida, M; Guida, S; Iacobazzi, RM; Maida, I; Porcelli, L; Quatrale, AE; Sidella, L; Stolfa, DA; Strippoli, S; Tommasi, S1
Kato, M; Kumasaka, MY; Nghia, PT; Thang, ND; Yajima, I1
Ascierto, PA; Bryce, A; Chmielowski, B; D'Angelo, SP; Grob, JJ; Grossmann, KF; Gutzmer, R; Hassel, JC; Hodi, FS; Hoeller, C; Horak, C; Khushalani, NI; Krackhardt, AM; Lambert, A; Lao, CD; Larkin, J; Linette, GP; Lorigan, P; Maio, M; Miller, WH; Minor, D; Mohr, P; Neyns, B; Svane, IM; Sznol, M; Thomas, L; Weber, JS; Yang, AS1
Aksoy, A; Arpaci, E; Berk, V; Gumusay, O; Ozaslan, E1
Alfano, D; Caputo, E; Cavalcanti, E; Fico, A; Patriarca, EJ; Travali, S; Valentino, A; Vasta, V1
Algazi, AP; Bastian, BC; Behr, S; Cha, E; Chong, K; Coakley, F; Cortez, B; Daud, AI; Hwang, J; Liu, S; McCalmont, T; Ortiz-Urda, SM; Pampaloni, MH; Quiroz, A1
Abhyankar, S; Chang, CL; Donga, P; Munakata, J; Reyes, CM; Schabert, VF; Yim, YM1
Gong, T; Shen, H; Shi, S; Sun, X; Zhang, Z1
Jang, GH; Kim, NY; Lee, M1
Chen, H; Li, Q; Peng, L; Xiong, W1
Ahmed, W; Elhissi, AM; Fan, M; Phoenix, DA; Sun, X; Wan, KW; Xu, H; Zhang, Z1
Gao, H; He, Q; Qiu, Y; Yuan, M; Zhang, L1
Jasti, B; Li, X; Saraf, P; Wrischnik, L1
Azzariti, A; Guida, G; Guida, M; Porcelli, L; Tommasi, S1
Ding, Y; Guo, YQ; Li, DD; Li, JJ; Peng, RQ; Wen, XZ; Zhang, X; Zhang, XS1
D'Andrea, K; Flaherty, KT; Khare, S; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Roszik, J; Schuchter, LM; Wilson, MA; Woodman, SE; Wubbenhorst, B; Zhao, F1
Carlino, MS; Long, GV1
Agarwala, SS; Bhatia, S; Brachmann, C; Brown, MP; Clawson, A; Conry, R; Del Vecchio, M; Elias, I; Ernst, S; Grob, JJ; Gutzmer, R; Hauschild, A; Haydon, A; Hersh, EM; Homsi, J; Karnoub, M; Kefford, R; Kendra, K; Li, M; Loquai, C; Renschler, MF; Robert, C; Testori, A1
Leon-Ferre, RA; Markovic, SN1
Kaluđerović, GN; Krajnović, T; Maksimović-Ivanić, D; Mijatović, S; Wessjohann, LA1
Casafont, Í; Fanarraga, ML; Fernández, F; García-Hevia, L; González, J; Valiente, R; Villegas, JC1
Cheng, PF; Dummer, R; Goldinger, SM; Guenova, E; Jaberg-Bentele, N; Kunz, M; Levesque, MP; Mangana, J; Nagel, HW; Nägeli, M; Thurneysen, S; Ziegler, M1
Abrams, KR; Amonkar, MM; Bell, H; Casey, M; Latimer, NR1
Duncan, B; Hou, S; Jeong, Y; Jiang, Y; Kim, C; Kim, CS; Kim, ST; Park, MH; Rotello, VM; Saha, K; Tang, R; Yan, B; Yeh, YC1
Ayub, M; Brady, G; Dhomen, N; Dive, C; Fusi, A; Garner, G; Girotti, MR; Gremel, G; Lee, RJ; Lorigan, P; Mandal, AK; Marais, R; Rothwell, DG; Valpione, S; Wallace, A; Wood, S1
Jia, DD; Jin, G; Li, T; Wu, H; Xia, LM; Zheng, AW1
Blank, C; Cranmer, L; Daud, A; Dummer, R; Ebbinghaus, S; Hamid, O; Hauschild, A; Hille, D; Kang, SP; Loquai, C; Mehnert, JM; O'Day, S; Puzanov, I; Ribas, A; Robert, C; Salama, A; Schachter, J; Schadendorf, D; van den Eertwegh, A; Zhou, W1
He, Q; Qiu, Y; Ruan, S; Shi, K; Tai, X; Xiang, B; Yang, Y; Zhang, Z1
Maesawa, C; Nishiya, M; Shibazaki, M; Yasuhira, S1
Huong, PT; Minh, NV; Thang, ND1
Chen, Q; Flowers, CR; Goldstein, DA; Kohn, CG; Montero, AJ; Zeichner, SB1
Amagai, M; Fujita, T; Fukuda, K; Funakoshi, T; Kawakami, Y; Mori, M; Nakamura, Y; Okamoto, M; Sakurai, T; Taguchi, J; Tanese, K; Tanikawa, A1
Hu, J; Huang, Y; Huang, Z; Liu, H; Peng, B; Su, Y; Xie, N1
Basu, R; Baumgaertel, N; Kopchick, JJ; Wu, S1
Chopitea, A; Díaz-Lagares, A; Espinós, J; González, A; González-Cao, M; Martín-Algarra, S; Nieto, Y; Ponz, M; Redondo, P; Viteri, S1
Ghaidi, F; Joshi, B; Kojic, LD; Nabi, IR; Nedev, H; Saragovi, HU; Wiseman, SM1
Brindley, DN; Gaetano, C; Goping, IS; Samadi, N1
Amatruda, T; Constantinou, CL; Egner, JR; Fitch, TR; Jilani, SZ; Kottschade, LA; Markovic, SN; Morton, RF; Perez, DG; Suman, VJ1
Akasaka, K; Akasaka, T; Maeda, F; Maesawa, C; Masuda, T; Shibazaki, M; Takahashi, K1
Gude, RP; Murthy, RS; Rajyaguru, TH; Shenoy, VS1
Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C1
Domb, AJ; Shikanov, A; Shikanov, S; Vaisman, B1
Agarwala, SS; Daud, A; Eggermont, A; Garbe, C; Gille, J; Gonzalez, R; Grabbe, S; Hauschild, A; Hersey, P; Hogg, D; Keilholz, U; Kirkwood, JM; O'Day, S; Patel, K; Peschel, C; Robert, C; Schadendorf, D; Trefzer, U; White, JM; Xia, C1
Adams, VR; Cho, MJ; Dong, X; Liu, Y; Mattingly, CA; Mumper, RJ; Tseng, MT1
Berneburg, M; Clasen, S; Eigentler, T; Forschner, A; Garbe, C; Guenova, E; Knaudt, B; Leiter, U; Meier, F; Zielinski, C1
D'Agnano, I; Felsani, A; Florenzano, F; Gatti, G; Maresca, G; Natoli, M; Nicolin, A1
Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S1
Alexandrescu, DT; Dasanu, CA; Ichim, TE; Kabigting, F1
Bedikian, A; Gerber, DL; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Ring, S1
Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Kim, KB; Mahoney, SL; Papadopoulos, NE2
Anderson, C; Gonzalez, R; Haddad, J; Hutchins, L; Jacobson, E; Kong, S; Lawson, D; O'Day, S; Weber, R; Williams, A1
Clawson, AA; Gonzalez, R; Gordon, MS; Hersh, EM; O'Day, SJ; Ribas, A; Samlowski, WE; Shechter, DE1
Atkins, MB; Bhatt, RS; Heymach, JV; McDermott, D; Merchan, J; Parker, R; Seery, V; Sukhatme, VP; Wu, HK; Zhang, L1
Li, Z; Wang, J; Yang, T; Yin, J; Zhang, Q; Zhang, X1
Balkissoon, J; Boxall, J; Chaplin, DJ; Ganesan, TS; Gaya, A; Nathan, PD; Poupard, L; Rustin, GJ; Shreeves, G; Stratford, MR; Wang, D; Zweifel, M1
Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ1
Agarwala, S; Bedikian, AY; Conry, R; DeConti, RC; Ernstoff, M; Kim, KB; Papadopoulos, N1
Bedikian, AY; Homsi, J; Hwu, P; Hwu, WJ; Johnson, MM; Kim, KB; McIntyre, S; Papadopoulos, NE; Rohlfs, M; Warneke, CL1
Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF1
Berneburg, M; Eigentler, TK; Garbe, C; Ikenberg, K; Keim, U; Leiter, U; Pflugfelder, A; Weide, B1
Bröcker, EB; Klink, T; Meyer, KM; Ugurel, S1
Amatruda, T; Behrens, R; Fitch, TR; Jaslowski, AJ; Kottschade, LA; Markovic, SN; Mattar, BI; McWilliams, RR; Nikcevich, DA; Suman, VJ1
Sevko, A; Umansky, V1
Carson, WE; Chen, D; Cheverton, P; Fruehauf, JP; Kim, KB; Linette, GP; Markovic, SN; McDermott, DF; Nguyen, H; O'Day, SJ; Peterson, AC; Sosman, JA; Weber, JS1
Asensi, M; Brown, BD; Cerdá, M; Estrela, JM; Mena, S; Obrador, E; Ortega, A; Petschen, I; Priego, S; Rodriguez, ML1
Bhaskar, S; Chandra, S; Mamilapally, S; Roy, A; Upadhyay, P1
Juergens, R; Levine, MN1
Barlesi, F; Bondarenko, I; Chacko, R; Cuillerot, JM; Lu, H; Luft, A; Lynch, TJ; Neal, J; Reck, M; Sebastian, M; Serwatowski, P1
Ahn, NG; Dallaglio, K; Ellis, LZ; Fujita, M; Gonzalez, R; Lewis, KD; Liu, W; Luo, Y; McCarter, MD; Norris, DA; Robinson, SE; Robinson, WA; Roop, DR; Spritz, RA; Takeda, M1
Dong, J; Guan, M; Wong, PF; Wu, J; Xu, J; Yu, H1
Jasti, B; Javali, NM; Li, X; Raj, A; Saraf, P1
Kim, KB1
Amatruda, TT; Cohen, PA; Geoffroy, FJ; Gross, HM; Jaslowski, AJ; Kaur, JS; Kosel, ML; Kottschade, LA; Markovic, SN; McWilliams, RR; Perez, DG; Suman, VJ1
Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM1
Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y1
Bertin, R; Bolcato, J; Caparrotta, L; Chen, Z; Froldi, G; Montopoli, M1
Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS1
Atkins, MB; Flaherty, KT; Flaherty, L; Kefford, R; Kirkwood, JM; Lee, SJ; Leming, P; Schuchter, LM; Zhao, F1
Beckhove, P; Kato, M; Michels, T; Sevko, A; Shurin, GV; Shurin, MR; Umansky, L; Umansky, V; Vrohlings, M1
Bahcall, S; Chiarion-Sileni, V; Collichio, F; Eggermont, AM; Friedlander, P; Garbe, C; Grob, JJ; Guo, W; Hauschild, A; Kefford, R; Lufkin, J; Mackiewicz, J; Mortier, L; O'Day, SJ; Robert, C; Schachter, J; Testori, A; Ugurel, S; Vukovic, V1
Cappugi, P; Coronnello, M; Giannotti, B; Mini, E; Pimpinelli, N; Prignano, F1
Li, Y; McClay, EF1
Aglione, S; Bajetta, E; Bernard-Marty, C; Buzzoni, R; Del Vecchio, M; Khayat, D; Nova, P; Rixe, O; Taillibert, S; Vitali, M1
Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G1
Dicker, AP; Grant, DS; Williams, TL; Zahaczewsky, M1
Aydiner, A; Camlica, H; Kurul, S; Tas, F; Topuz, E1
Entin, I; Keisari, Y; Korenstein, R; Plotnikov, A1
Bergstralh, DT; Clements, C; MacKeigan, JP; Taxman, DJ; Ting, JP1
Baraldi, PG; Borea, PA; Capitani, S; Gessi, S; Leung, E; Merighi, S; Mirandola, P; Tabrizi, MA; Varani, K1
Becker, JC; Figl, R; Hauschild, A; Hofmann, U; Keller, I; Schadendorf, D; Trefzer, U; Zimpfer-Rechner, C1
Bedikian, AY; Ellerhorst, J; Eton, O; Papadopoulos, N; Plager, C; Smith, T1
Brandwijk, RJ; Dings, RP; Griffioen, AW; Thijssen, VL1
Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG1
Baguley, BC; Basse, B; Joseph, WR; Marshall, ES; van Brunt, B; Wake, G; Wall, DJ1
Azzabi, A; Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Hughes, AN; Kelly, C; Lind, MJ; Maraveyas, A; Plummer, ER; Todd, R1
Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M1
Albertini, MR; Dietrich, L; Eastman, M; Kim, K; King, DM; Kwak, M; Schalch, H; Walker, L1
Creagan, ET; Croghan, GA; Holtan, SG; Ingle, JN; Kaur, JS; Kottschade, LA; Markovic, SN; Pitot, HC; Rao, RD1
Becker, S; Brix, G; Dellian, M; Eichhorn, ME; Griebel, J; Jauch, KW; Michaelis, U; Ruhstorfer, H; Sauer, B; Strieth, S; Teifel, M; Werner, A1
Agarwala, S; Argiris, A; Bergsland, E; Rugo, H; Wanebo, HJ1
Chiba, N; Hanada, M; Ishioka, C; Kakudo, Y; Kato, S; Noguchi, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Shimodaira, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T1
Anichini, A; Ballatore, C; Felding-Habermann, B; Janda, KD; Kaufmann, GF; Kim, Y; Lillo, AM; Liu, Y; Mortarini, R; Steiniger, SC; Zhou, B1
Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J1
Baeuerle, PA; Clark, D; Freimark, B; Nickel, J; Pernasetti, F; Van Epps, D1
Ferrara, KW; LaBell, R; Lum, AF; Matsunaga, TO; McCallan, J; Stieger, SM; Tartis, MS1
Collichio, FA; Dees, EC; Goldberg, RM; Hawkins, MJ; Ivanova, A; Lindley, C; Mu, H; O'Neil, BH; Socinski, MA; Stinchcombe, TE; Walko, CM1
Aristu, J; Garrán, C; González Cao, M; Martín Algarra, S; Nieto, Y; Ponz, M; Viteri, S1
Bartlett, DL; Brown, CK; Demarco, RA; Dong, Xda E; Ito, N; Lotze, MT; Popovic, P; Shand, SH; Watkins, S; Winikoff, S; Zeh, HJ1
Clement, MV; Lee, SC; Pervaiz, S; Sim, N; Yadav, SK1
Haikel, Y; Hassan, M; Hengge, UR; Selimovic, D1
Tuma, RS1
Bissery, MC; Dykes, DJ; Harrison, SD; Waud, WR1
Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I1
Aamdal, S; Franklin, HR; Kaplan, S; Kerger, J; Paridaens, R; Schachter, J; Verweij, J; Wanders, J; Wolff, I1
DeLisa, AF; Gregory, RE1
Lakshmi, MS; Parker, C; Piura, B; Sherbet, GV1
Einzig, AI; Wiernik, PH1
Bedikian, AY; Burris, HA; Buzaid, AC; Eckardt, JR; Eton, O; Jenkins, J; Legha, SS; Smetzer, L; Von Hoff, DD; Weiss, GR1
Battafarano, DF; Burris, HA; Keeling, JH; Older, SA; Zimmerman, GC1
Mackenzie, H; Mohith, A; Retsas, S1
Mohith, A; Photiou, A; Retsas, S1
Hájek, R; Slavik, M; Vorlicek, J1
Hunter, NR; Inoue, T; Kim, EE; Li, C; Milas, L; Wallace, S; Yang, DJ; Yu, D1
Coatsworth, S; Einzig, AI; Recio, A; Rodriquez, R; Schuchter, LM; Wiernik, PH1
Leong, LK; Moss, J; Photiou, A; Retsas, S; Shah, P1
Bujor, L; Caffau, C; Favaro, D; Gobitti, C; Quaia, M; Robieux, I; Santarosa, M; Spada, A; Trovò, MG; Zanelli, GD1
Banerjee, S; Brown, DL; Fallis, AG1
Bhuyan, BK; Lopes, NM; Miller, HP; Young, ND1
Benson, LT; Einzig, AI; Kaplan, J; Tan, V; Tentoramano, L; Wadler, S; Wiernik, PH1
Bernard, S; Brouwer, KL; Gonzalez, P; Lawrence, P; Letrent, SP; Mudd, PN; Radomski, KM; Socinski, MA; Steagall, A1
Orel, NF1
Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN1
Bohling, CA; Forrest, LJ; Hershey, AE; Imondi, AR; Kurzman, ID; Placke, ME; Stonerook, M; Vail, DM1
Berd, D; Mastrangelo, MJ; Nathan, FE; Sato, T1
Bani, MR; Ben-David, Y; Chu, W; Kapoor, M; Kerbel, RS; Lu, SJ; Pak, BJ; Tamir, A1
Constantinides, PP; Kessler, D; Lalji, S; Lambert, KJ; Ma, W; Quay, SC; Schneider, B; Tustian, AK; Wentzel, B; Worah, D1
Chen, ZJ; Hopper, E; Murphy, M; Shen, H; Tew, KD; Zilfou, JT1
Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D1
Feun, LG; Hurley, J; Marini, A; Savaraj, N1
Clark, J; Finkelstein, DM; Haluska, FG; Hodi, FS; Soiffer, RJ1
Cohen, SM1
Dutcher, JP; Einzig, AI; Garowski, E; Hochster, H; Sasloff, J; Smith, TJ; Trump, DL; Wiernik, PH1
Einzig, AI; Schwartz, EL; Wiernik, PH1
Glover, DJ1
Benjamin, RS; Legha, SS; Papadopoulos, N; Raber, M; Ring, S1
Baker, JR; Donehower, RC; Gralla, RJ; Leyland-Jones, B; Ohnuma, T; Trump, DL; Van Echo, DA; Von Hoff, DD; Weiss, RB; Wiernik, PH1
Slichenmyer, WJ; Von Hoff, DD1
Dutcher, JP; Einzig, A; Lipton, RB; Schwartz, EL; Strauman, JJ; Wiernik, PH1
Berger, A; Böcker, A; Burkard, M; Busch, C; Donaubauer, K; Frank, J; Garbe, C; Lauer, UM; Leischner, C; Niessner, H; Riepl, H; Sinnberg, T; Urmann, C; Venturelli, S1

Reviews

17 review(s) available for paclitaxel and Melanoma

ArticleYear
Advanced Acral Melanoma Therapies: Current Status and Future Directions.
    Current treatment options in oncology, 2022, Volume: 23, Issue:10

    Topics: Albumins; Angiogenesis Inhibitors; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interferons; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Tumor Microenvironment

2022
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 123

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib

2019
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
    Medicine, 2018, Volume: 97, Issue:31

    Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimumab; Melanoma; Paclitaxel; Sulfonamides; Temozolomide; Vemurafenib

2018
Efficacy of nab-paclitaxel in treating metastatic melanoma.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:5

    Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Temozolomide

2019
What is the role of chemotherapy in the treatment of melanoma?
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunosuppression Therapy; Immunotherapy; Ipilimumab; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Temozolomide; Treatment Outcome

2014
Nab-paclitaxel in patients with metastatic melanoma.
    Expert review of anticancer therapy, 2015, Volume: 15, Issue:12

    Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Skin Neoplasms

2015
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
    Melanoma research, 2011, Volume: 21, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Logistic Models; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Remission Induction; Sex Factors; Skin Neoplasms; Treatment Outcome; Vinblastine

2011
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
    Cancer, 2013, Feb-01, Volume: 119, Issue:3

    Topics: Albumins; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Skin Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A

2013
Systemic chemotherapy for the treatment of metastatic melanoma.
    Seminars in oncology, 2002, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide

2002
Metastatic melanoma: chemotherapy.
    Seminars in oncology, 2002, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Cytokines; Dacarbazine; Genetic Therapy; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Paclitaxel; Tamoxifen; Taxoids; Thalidomide

2002
Targeting growth factors and angiogenesis; using small molecules in malignancy.
    Cancer metastasis reviews, 2006, Volume: 25, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Genes, ras; Humans; Melanoma; Nanostructures; Neoplasms; Paclitaxel; Proto-Oncogene Proteins B-raf; Receptors, Growth Factor; Signal Transduction

2006
Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
    Clinical pharmacy, 1993, Volume: 12, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins

1993
Taxol in malignant melanoma.
    Journal of the National Cancer Institute. Monographs, 1993, Issue:15

    Topics: Clinical Trials as Topic; Humans; Melanoma; Paclitaxel

1993
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Neoplasma, 1996, Volume: 43, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Melanoma; Microtubules; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Paclitaxel

1996
[Taxotere in various solid tumors].
    Voprosy onkologii, 1998, Volume: 44, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms

1998
Taxol: a new agent active in melanoma and ovarian cancer.
    Cancer treatment and research, 1991, Volume: 58

    Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Melanoma; Microtubules; Ovarian Neoplasms; Paclitaxel

1991
New natural products in cancer chemotherapy.
    Journal of clinical pharmacology, 1990, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan

1990

Trials

68 trial(s) available for paclitaxel and Melanoma

ArticleYear
Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261
    American journal of clinical oncology, 2020, Volume: 43, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Ipilimumab; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Time Factors

2020
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-10, Volume: 39, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mucous Membrane; Paclitaxel; Prognosis; Survival Rate

2021
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 09-01, Volume: 27, Issue:17

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides

2021
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
    Nature communications, 2017, 09-19, Volume: 8, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B-Lymphocytes; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Insulin-Like Growth Factor I; Lymphocytes, Tumor-Infiltrating; Melanoma; Paclitaxel; Pilot Projects; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, Fibroblast Growth Factor, Type 3; Skin Neoplasms; Tumor Microenvironment

2017
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
    Cancer, 2018, 02-01, Volume: 124, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Everolimus; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf

2018
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:2

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Pyrimidines; Sulfonamides

2018
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 02-01, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Indazoles; Male; Melanoma; Middle Aged; Mutation; Paclitaxel; Prognosis; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides; Survival Rate

2019
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
    Melanoma research, 2013, Volume: 23, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Paclitaxel; Sirolimus; Skin Neoplasms; Treatment Outcome

2013
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Health Status; Humans; MAP Kinase Kinase Kinases; Melanoma; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quality of Life; Surveys and Questionnaires

2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
    Cancer, 2014, Jul-01, Volume: 120, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy-Induced Febrile Neutropenia; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Skin Neoplasms; Sulfonamides; Thrombocytopenia; Treatment Outcome

2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-15, Volume: 20, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate

2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Pyridones; Pyrimidinones; Skin Neoplasms

2015
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
    American journal of clinical oncology, 2015, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Treatment Outcome

2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CTLA-4 Antigen; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf

2015
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
    British journal of cancer, 2015, Apr-14, Volume: 112, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Dideoxynucleosides; Female; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiography; Treatment Outcome

2015
Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult

2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; Double-Blind Method; Genes, ras; Humans; Melanoma; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Sorafenib; Treatment Outcome

2016
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Young Adult

2015
An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.
    The British journal of dermatology, 2016, Volume: 175, Issue:5

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Drug Administration Schedule; Female; Humans; Indazoles; Infusions, Intravenous; Male; Melanoma; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides; Treatment Outcome; Up-Regulation

2016
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
    Cancer medicine, 2016, Volume: 5, Issue:5

    Topics: Antineoplastic Agents; Dacarbazine; Disease Progression; Drug Substitution; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Survival Analysis

2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 67

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Disease-Free Survival; Female; Health Status; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Skin Neoplasms; Temozolomide; Young Adult

2016
Targeting Both Tumor and Stroma Cells to Treat Melanoma: NIPAWILMA.
    Oncology research and treatment, 2016, Volume: 39, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Skin Neoplasms; Stromal Cells; Survival Rate; Treatment Outcome; Young Adult

2016
Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
    Melanoma research, 2017, Volume: 27, Issue:4

    Topics: Adult; Aged; Cancer Vaccines; Carboplatin; Dendritic Cells; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Peptide Fragments; Pilot Projects; Skin Neoplasms

2017
Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.
    Oncology, 2008, Volume: 74, Issue:1-2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Prospective Studies; Skin Neoplasms; Treatment Outcome

2008
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
    Cancer, 2009, Jan-01, Volume: 115, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A

2009
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome

2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-10, Volume: 27, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Treatment Outcome; Young Adult

2009
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    American journal of clinical oncology, 2009, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome

2009
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
    Melanoma research, 2009, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Exanthema; Fatigue; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Pain; Skin Neoplasms; Survival Rate; Tumor Burden

2009
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Humans; Hydrazines; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome

2009
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Cancer, 2010, Jan-01, Volume: 116, Issue:1

    Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms

2010
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
    Cancer, 2010, Apr-01, Volume: 116, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cytokines; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Pyrazoles; Skin Neoplasms; Sulfonamides

2010
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
    British journal of cancer, 2010, Apr-27, Volume: 102, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Life Expectancy; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Patient Selection; Stilbenes

2010
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
    Cancer, 2010, Jul-15, Volume: 116, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms

2010
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel

2011
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.
    Melanoma research, 2010, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Uveal Neoplasms

2010
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
    Melanoma research, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Small Cell Lung Carcinoma; Temozolomide

2011
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
    Cancer, 2011, Apr-15, Volume: 117, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms

2011
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-01, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Treatment Outcome

2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-10, Volume: 30, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Placebos; Proportional Hazards Models; Treatment Outcome

2012
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
    Cancer, 2013, Feb-01, Volume: 119, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Paclitaxel; Skin Neoplasms; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult

2013
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
    Cancer biology & therapy, 2012, Volume: 13, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome

2012
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Paclitaxel; Skin Neoplasms; Temozolomide; Thionucleotides; Treatment Outcome

2013
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms

2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib

2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Mar-20, Volume: 31, Issue:9

    Topics: Antineoplastic Agents, Phytogenic; Disease-Free Survival; Double-Blind Method; Humans; Hydrazines; L-Lactate Dehydrogenase; Melanoma; Paclitaxel; Skin Neoplasms; Treatment Outcome

2013
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
    Oncology, 2002, Volume: 63, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids

2002
Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2003, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome

2003
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG).
    Melanoma research, 2003, Volume: 13, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Male; Melanoma; Paclitaxel; Time Factors; Treatment Outcome

2003
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
    Melanoma research, 2004, Volume: 14, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Choroid Neoplasms; Disease Progression; Female; Humans; Injections, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome

2004
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
    International journal of cancer, 2005, Jan-20, Volume: 113, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Isoenzymes; Laminin; Lung; Male; Melanoma; Membrane Proteins; Neovascularization, Pathologic; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteoglycans; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Cells, Cultured; Umbilical Veins

2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
    British journal of cancer, 2005, Mar-28, Volume: 92, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Temozolomide

2005
Phase II trial of weekly paclitaxel in patients with advanced melanoma.
    Melanoma research, 2005, Volume: 15, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Survival Rate

2005
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-15, Volume: 12, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome

2006
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:5

    Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Paclitaxel

2007
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A Suppl 4

    Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids

1995
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Taxoids

1994
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Taxoids

1995
Taxol and vinorelbine: a new active combination for disseminated malignant melanoma.
    Anti-cancer drugs, 1996, Volume: 7, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine

1996
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
    Medical oncology (Northwood, London, England), 1996, Volume: 13, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids

1996
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
    Investigational new drugs, 1998, Volume: 16, Issue:1

    Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel

1998
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
    Anti-cancer drugs, 1998, Volume: 9, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Time Factors

1998
Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.
    Cancer, 2000, Jan-01, Volume: 88, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Mucous Membrane; Paclitaxel; Skin Neoplasms; Tamoxifen; Treatment Outcome

2000
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia

2002
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
    Cancer investigation, 2002, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nervous System Diseases; Paclitaxel; Skin Neoplasms; Treatment Outcome

2002
Phase II study of paclitaxel and carboplatin for malignant melanoma.
    American journal of clinical oncology, 2002, Volume: 25, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel

2002
A phase II study of taxol in patients with malignant melanoma.
    Investigational new drugs, 1991, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Paclitaxel

1991
Taxol: a new agent active in melanoma and ovarian cancer.
    Cancer treatment and research, 1991, Volume: 58

    Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Melanoma; Microtubules; Ovarian Neoplasms; Paclitaxel

1991

Other Studies

171 other study(ies) available for paclitaxel and Melanoma

ArticleYear
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
    Journal of natural products, 2001, Volume: 64, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine

2001
Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.
    Journal of medicinal chemistry, 2001, Dec-20, Volume: 44, Issue:26

    Topics: Allantois; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biopolymers; Cattle; Chorion; Drug Screening Assays, Antitumor; G2 Phase; GTP Phosphohydrolases; Humans; In Vitro Techniques; Indoles; Melanoma; Mice; Mice, Nude; Mitosis; Structure-Activity Relationship; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured

2001
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
    Journal of natural products, 2002, Volume: 65, Issue:6

    Topics: Animals; Biological Factors; Colonic Neoplasms; Diosgenin; Disease Models, Animal; Diterpenes; Drug Screening Assays, Antitumor; Female; Heterocyclic Compounds, 3-Ring; HL-60 Cells; Humans; Inhibitory Concentration 50; KB Cells; Leukemia P388; Male; Melanoma; Mice; Molecular Structure; Naphthoquinones; Ovarian Neoplasms; Paclitaxel; Polymers; Prostatic Neoplasms; Triterpenes; Tumor Cells, Cultured

2002
Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents.
    Bioorganic & medicinal chemistry letters, 2004, Aug-16, Volume: 14, Issue:16

    Topics: Cell Line; Humans; Melanoma; Oligopeptides; Structure-Activity Relationship; Transplantation, Heterologous; Tubulin Modulators

2004
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.
    Journal of medicinal chemistry, 2012, Aug-23, Volume: 55, Issue:16

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imidazoles; Male; Melanoma; Models, Molecular; Paclitaxel; Prostatic Neoplasms; Structure-Activity Relationship; Tubulin Modulators

2012
Cytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharum.
    Journal of natural products, 2014, Jun-27, Volume: 77, Issue:6

    Topics: Animals; Antineoplastic Agents; Ascomycota; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disease Models, Animal; Drug Screening Assays, Antitumor; Humans; Melanoma; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Piperazines

2014
Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
    Journal of medicinal chemistry, 2018, 02-22, Volume: 61, Issue:4

    Topics: Animals; Apoptosis; Binding Sites; Colchicine; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Heterografts; Humans; Male; Melanoma; Polymerization; Prostatic Neoplasms; Pyrimidines; Tubulin

2018
Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.
    European journal of medicinal chemistry, 2018, Apr-10, Volume: 149

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Heterografts; Humans; Hydroxyquinolines; Indoles; Inhibitor of Apoptosis Proteins; Melanoma; Mice; Pyrrolidines; Structure-Activity Relationship; Survivin

2018
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
    Journal of medicinal chemistry, 2018, 09-13, Volume: 61, Issue:17

    Topics: Animals; Cell Proliferation; Chalcones; Humans; Male; Melanoma; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Protein Conformation; Tubulin; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2018
A Novel Anticancer Stem Cell Compound Derived from Pleuromutilin Induced Necroptosis of Melanoma Cells.
    Journal of medicinal chemistry, 2021, 11-11, Volume: 64, Issue:21

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diterpenes; Humans; Melanoma; Mice; Mice, Nude; Microbial Sensitivity Tests; Necroptosis; Neoplastic Stem Cells; Pleuromutilins; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2021
Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab-resistant acral and mucosal melanoma.
    The British journal of dermatology, 2022, Volume: 186, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Melanoma; Nivolumab; Paclitaxel; Skin Neoplasms

2022
Cancer microcell initiation and determination.
    BMC cancer, 2021, Oct-08, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Nucleus; Cell Self Renewal; Cell Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Endosomal Sorting Complexes Required for Transport; Female; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Indicators and Reagents; Melanoma; Microscopy, Electron; NADP; Neoplasm Recurrence, Local; Neoplasms; Neutral Red; Paclitaxel; Stress, Physiological; Time-Lapse Imaging; Transcription Factors; Transfection; Uterine Cervical Neoplasms

2021
Serotonin type-3 receptor antagonists selectively kill melanoma cells through classical apoptosis, microtubule depolymerisation, ERK activation, and NF-κB downregulation.
    Cell biology and toxicology, 2023, Volume: 39, Issue:3

    Topics: Antiemetics; Apoptosis; Down-Regulation; Humans; Melanoma; Molecular Docking Simulation; NF-kappa B; Ondansetron; Paclitaxel; Serotonin; Tropisetron; Vomiting

2023
Exosomes are secreted at similar densities by M21 and PC3 human cancer cells and show paclitaxel solubility.
    Biochimica et biophysica acta. Biomembranes, 2022, 04-01, Volume: 1864, Issue:4

    Topics: Cell Line, Tumor; Drug Carriers; Extracellular Vesicles; Humans; Male; Melanoma; Microscopy, Electron, Transmission; Paclitaxel; Prostatic Neoplasms; Solubility

2022
ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine.
    The Journal of clinical investigation, 2022, 03-01, Volume: 132, Issue:5

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Phosphatidylserines; Skin Neoplasms; Tumor Microenvironment

2022
Myrsinane-type diterpenes from Euphorbia gedrosiaca with cell growth inhibitory activity and apoptotic effects on melanoma cancer cells.
    Fitoterapia, 2022, Volume: 157

    Topics: Apoptosis; Cell Line, Tumor; Chromatography, Liquid; Diterpenes; Euphorbia; Flow Cytometry; Growth Inhibitors; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Paclitaxel; Plant Extracts

2022
The mechanisms of immune-chemotherapy with nanocomplex codelivery of pTRP-2 and adjuvant of paclitaxel against melanoma.
    Drug development and industrial pharmacy, 2021, Volume: 47, Issue:11

    Topics: Adjuvants, Immunologic; Animals; Humans; Melanoma; Mice; NF-kappa B; Paclitaxel; Toll-Like Receptor 4

2021
Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis.
    International journal of biological sciences, 2022, Volume: 18, Issue:4

    Topics: Animals; Cell Line, Tumor; Cell Movement; Chemokine CCL21; Ligands; Lymphatic Metastasis; Melanoma; Mice; Paclitaxel; Receptors, CCR7

2022
Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers.
    Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 345

    Topics: Biomimetics; Cell Line, Tumor; Drug Delivery Systems; Erythrocytes; Humans; Melanoma; Nanoparticles; Paclitaxel; Phosphatidylethanolamines; Polymers; Tumor Microenvironment

2022
An injectable thermosensitive hydrogel/nanomicelles composite for local chemo-immunotherapy in mouse model of melanoma.
    Journal of biomaterials applications, 2022, Volume: 37, Issue:3

    Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hydrogels; Immunotherapy; Melanoma; Mice; Micelles; Paclitaxel; Poloxamer

2022
A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:12

    Topics: Cisplatin; Dacarbazine; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Prognosis; RNA, Long Noncoding; RNA, Messenger; Skin Neoplasms; Tumor Microenvironment

2022
Simultaneous chemotherapy/sonodynamic therapy of the melanoma cancer cells using a gold-paclitaxel nanostructure.
    Photodiagnosis and photodynamic therapy, 2022, Volume: 39

    Topics: Cell Line, Tumor; Gold; Humans; Melanoma; Metal Nanoparticles; Nanoparticles; Paclitaxel; Photochemotherapy

2022
B16F10 Cell Membrane-Based Nanovesicles for Melanoma Therapy Are Superior to Hyaluronic Acid-Modified Nanocarriers.
    Molecular pharmaceutics, 2022, 08-01, Volume: 19, Issue:8

    Topics: Cell Line, Tumor; Cell Membrane; Humans; Hyaluronic Acid; Melanoma; Nanoparticles; Paclitaxel; Phospholipids; Polyethylene Glycols

2022
pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma.
    Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 350

    Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Cell Line, Tumor; Colchicine; Humans; Hydrogen-Ion Concentration; Lung; Lung Neoplasms; Melanoma; Mice; Nanomedicine; Paclitaxel; Polymers; Schiff Bases; Tubulin Modulators; Vincristine

2022
Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.
    International journal of molecular sciences, 2022, Aug-25, Volume: 23, Issue:17

    Topics: Antineoplastic Agents; Betulinic Acid; Cell Line; Docetaxel; Humans; In Vitro Techniques; Melanoma; Melanoma, Cutaneous Malignant; Paclitaxel; Pentacyclic Triterpenes; Skin Neoplasms; Taxoids

2022
Synergetic effect of high dose rate radiations (10× FFF/2400 MU/min/10 MV x-rays) and paclitaxel selectively eliminates melanoma cells.
    Cancer reports (Hoboken, N.J.), 2023, Volume: 6, Issue:2

    Topics: Apoptosis; Humans; Melanoma; Paclitaxel; X-Rays

2023
Cocoa presents cytotoxicity against melanoma cancer cell lines (A-375 e B16-F10) and improves chemotherapy activity by increasing oxidative stress.
    Journal of food biochemistry, 2022, Volume: 46, Issue:12

    Topics: Antineoplastic Agents; Cacao; Cell Line, Tumor; Melanoma; Oxidative Stress; Paclitaxel

2022
Modification of α-Tocopherol Succinate with a Tumor-targeting Peptide Conjugate Enhances the Antitumor Efficacy of a Paclitaxel-loaded Lipid Aggregate.
    Chemistry, an Asian journal, 2023, Jan-17, Volume: 18, Issue:2

    Topics: alpha-Tocopherol; Animals; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasm; Lipids; Melanoma; Mice; Paclitaxel; Peptides

2023
Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel.
    International journal of molecular sciences, 2022, Dec-04, Volume: 23, Issue:23

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Flavonoids; Humans; Melanoma; Mice; Paclitaxel

2022
SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Cancer letters, 2023, 02-28, Volume: 555

    Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Colchicine; Humans; Male; Melanoma; Mice; Paclitaxel; Polymerization; Tubulin; Tubulin Modulators

2023
Multifunctional Modified Tumor Cell Membranes-Coated Adjuvant PTX against Melanoma.
    Biomolecules, 2023, 01-14, Volume: 13, Issue:1

    Topics: Cell Line, Tumor; Cell Membrane; Drug Carriers; Humans; Melanoma; Paclitaxel

2023
In situ administration of temperature-sensitive hydrogel composite loading paclitaxel microspheres and cisplatin for the treatment of melanoma.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 160

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cisplatin; Hydrogels; Melanoma; Mice; Microspheres; Paclitaxel; Temperature

2023
Development of Nanocarrier-Based Radionuclide and Photothermal Therapy in Combination with Chemotherapy in Melanoma Cancer Treatment.
    ACS applied materials & interfaces, 2023, Mar-15, Volume: 15, Issue:10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Gold; Humans; Melanoma; Nanotubes; Paclitaxel; Phototherapy; Photothermal Therapy; Radioisotopes

2023
Topical Cream Carrying Drug-Loaded Nanogels for Melanoma Treatment.
    Pharmaceutical research, 2023, Volume: 40, Issue:10

    Topics: Animals; Cell Line, Tumor; Drug Carriers; Humans; Melanoma; Mice; Micelles; Nanogels; Paclitaxel; Polyethylene Glycols

2023
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
    Molecules (Basel, Switzerland), 2023, May-05, Volume: 28, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Mitoxantrone; Paclitaxel; Vemurafenib

2023
Synthesis and characterization of dual light/temperature-responsive supramolecular injectable hydrogel based on host-guest interaction between azobenzene and starch-grafted β-cyclodextrin: Melanoma therapy with paclitaxel.
    Carbohydrate polymers, 2023, Aug-01, Volume: 313

    Topics: beta-Cyclodextrins; Humans; Hydrogels; Melanoma; Paclitaxel; Polymers; Temperature

2023
Talin2 and KANK2 functionally interact to regulate microtubule dynamics, paclitaxel sensitivity and cell migration in the MDA-MB-435S melanoma cell line.
    Cellular & molecular biology letters, 2023, Jul-17, Volume: 28, Issue:1

    Topics: Actins; Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Cytoskeletal Proteins; Humans; Integrins; Melanoma; Microtubules; Paclitaxel; Protein Isoforms; Talin

2023
Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events.
    Immunotherapy, 2023, Volume: 15, Issue:13

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ipilimumab; Melanoma; Nivolumab; Paclitaxel; Skin Neoplasms; Syndrome

2023
Measuring Melanoma Nanomechanical Properties in Relation to Metastatic Ability and Anti-Cancer Drug Treatment Using Scanning Ion Conductance Microscopy.
    Cells, 2023, 10-04, Volume: 12, Issue:19

    Topics: Actins; Antineoplastic Agents; Cisplatin; Dacarbazine; Humans; Melanoma; Microscopy, Atomic Force; Paclitaxel

2023
Antitumour effects of Liporaxel (oral paclitaxel) for canine melanoma in a mouse xenograft model.
    Veterinary and comparative oncology, 2020, Volume: 18, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Dogs; Female; Melanoma; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel

2020
SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma.
    Molecular carcinogenesis, 2020, Volume: 59, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Multidrug Resistance-Associated Proteins; Paclitaxel; Side-Population Cells; SOXB1 Transcription Factors; Transcriptional Activation

2020
Low-dose paclitaxel via hyaluronan-functionalized bovine serum albumin nanoparticulate assembly for metastatic melanoma treatment.
    Journal of materials chemistry. B, 2020, 03-11, Volume: 8, Issue:10

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cations; Cell Movement; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Hyaluronic Acid; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms, Experimental; Paclitaxel; Particle Size; Serum Albumin, Bovine; Surface Properties; Tumor Cells, Cultured

2020
Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier.
    Journal of controlled release : official journal of the Controlled Release Society, 2020, 09-10, Volume: 325

    Topics: Apoptosis; Cell Line, Tumor; Humans; Liposomes; Melanoma; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Microenvironment

2020
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
    Journal of cancer research and therapeutics, 2020, Volume: 16, Issue:2

    Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Female; Humans; Infusions, Intra-Arterial; Melanoma; Middle Aged; Paclitaxel; Patient Safety; Rectal Neoplasms; Temozolomide; Treatment Outcome

2020
Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
    Cellular immunology, 2021, Volume: 360

    Topics: Aged; CD8-Positive T-Lymphocytes; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Melanoma; Middle Aged; Myeloid-Derived Suppressor Cells; Paclitaxel; Pilot Projects; Skin Neoplasms; Tumor Microenvironment

2021
Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
    Anticancer research, 2021, Volume: 41, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Melanoma; Metformin; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms

2021
ATR Inhibitors and Paclitaxel in Melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 09-01, Volume: 27, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Humans; Melanoma; Paclitaxel; Protein Kinase Inhibitors

2021
Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:5

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Humans; Immune Checkpoint Inhibitors; Melanoma; Paclitaxel; Retrospective Studies; Skin Neoplasms

2022
Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAF
    International journal of pharmaceutics, 2021, Sep-05, Volume: 606

    Topics: Animals; Cell Line, Tumor; Flavonoids; Humans; Melanoma; Mice; Mitogen-Activated Protein Kinase Kinases; Nanoparticles; Paclitaxel; Particle Size; Proto-Oncogene Proteins B-raf

2021
Fattigation-platform theranostic nanoparticles for cancer therapy.
    Materials science & engineering. C, Materials for biological applications, 2017, Jun-01, Volume: 75

    Topics: Animals; Cell Line, Tumor; Coated Materials, Biocompatible; Gelatin; Magnetite Nanoparticles; Melanoma; Mice; Neoplasms, Experimental; Oleic Acid; Paclitaxel; Silicon Dioxide; Theranostic Nanomedicine

2017
DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.
    Molecules and cells, 2017, May-31, Volume: 40, Issue:5

    Topics: AC133 Antigen; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice, Inbred BALB C; MicroRNAs; Neoplastic Stem Cells; Paclitaxel; SOXB1 Transcription Factors; Xenograft Model Antitumor Assays

2017
Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Nov-15, Volume: 109

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Ceramides; Drug Carriers; Emulsions; Melanoma; Nanoparticles; Paclitaxel; Skin; Skin Absorption; Swine; Triglycerides

2017
Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC cancer, 2018, 02-27, Volume: 18, Issue:1

    Topics: Acetates; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Interleukin-6; Interleukin-8; Melanoma; Paclitaxel; Signal Transduction; Toll-Like Receptor 4; Tumor Microenvironment; Tyramine

2018
Combined Action of PGRPs-Hsp70 Cytotoxic Complex with Paclitaxel Improves Outcomes of Melanoma Treatment in Mice.
    Bulletin of experimental biology and medicine, 2018, Volume: 164, Issue:5

    Topics: Animals; Antineoplastic Agents; HSP70 Heat-Shock Proteins; Kaplan-Meier Estimate; Melanoma; Mice; Mice, Inbred DBA; Paclitaxel; Recombinant Proteins

2018
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
    JCI insight, 2018, 04-19, Volume: 3, Issue:8

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; CD8-Positive T-Lymphocytes; CX3C Chemokine Receptor 1; Cytotoxins; Drug Therapy, Combination; Female; Granzymes; Humans; Immunotherapy; Male; Melanoma; Mice; Neoplasms; Paclitaxel; Perforin; Programmed Cell Death 1 Receptor

2018
Temporary suppression the sequestrated function of host macrophages for better nanoparticles tumor delivery.
    Drug delivery, 2018, Volume: 25, Issue:1

    Topics: Animals; Antineoplastic Agents; Biological Availability; Clodronic Acid; Drug Carriers; Lactic Acid; Liposomes; Liver; Macrophages; Melanoma; Mice; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tissue Distribution

2018
Complete Response of Metastatic Melanoma to Second Line Chemotherapy with Paclitaxel and Carboplatin - Case Report.
    Acta medica academica, 2018, Volume: 47, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Melanoma; Middle Aged; Paclitaxel; Prognosis; Treatment Outcome

2018
Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.
    Journal of controlled release : official journal of the Controlled Release Society, 2018, 10-28, Volume: 288

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line; Humans; Hydroxychloroquine; Integrin alphaVbeta3; Liposomes; Lung Neoplasms; Melanoma; Mice, Inbred C57BL; Neuropilin-1; Oligopeptides; Paclitaxel; Paxillin; Phosphatidylethanolamines; Polyethylene Glycols; Receptors, CXCR4

2018
A robust control system for targeting melanoma by a supermolecular DDMC/paclitaxel complex.
    Integrative biology : quantitative biosciences from nano to macro, 2018, 09-17, Volume: 10, Issue:9

    Topics: Allosteric Site; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DEAE-Dextran; Female; Humans; Kinetics; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Paclitaxel; Particle Size; Signal Transduction; Tumor Microenvironment; Zalcitabine

2018
Enhanced Transdermal Drug Delivery by Transfersome-Embedded Oligopeptide Hydrogel for Topical Chemotherapy of Melanoma.
    ACS nano, 2018, 10-23, Volume: 12, Issue:10

    Topics: Administration, Topical; Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell-Penetrating Peptides; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hydrogels; Melanoma; Mice; Mice, Nude; Oligopeptides; Paclitaxel; Skin Neoplasms

2018
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.
    Cell death & disease, 2018, 09-11, Volume: 9, Issue:9

    Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; Humans; Melanoma; Paclitaxel; Protein Kinase Inhibitors; Retrospective Studies; Tumor Protein p73; Tumor Suppressor Protein p53

2018
Retinoic acid increases the anticancer effect of paclitaxel by inducing differentiation of cancer stem cells in melanoma.
    Die Pharmazie, 2018, 12-01, Volume: 73, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Neoplastic Stem Cells; Paclitaxel; SOXB1 Transcription Factors; Tretinoin

2018
The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma.
    Acta oncologica (Stockholm, Sweden), 2019, Volume: 58, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor; Retrospective Studies

2019
Targeting the MAPK pathway in advanced BRAF wild-type melanoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4

    Topics: Humans; Indazoles; Melanoma; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Sulfonamides

2019
A sinister black finding in the stomach.
    Lancet (London, England), 2019, Mar-16, Volume: 393, Issue:10176

    Topics: Acrylonitrile; Aged; Aniline Compounds; Barrett Esophagus; Benzimidazoles; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma; Mutation; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach; Tomography, X-Ray Computed; Tubulin Modulators; Uveal Neoplasms

2019
In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.
    International journal of pharmaceutics, 2019, Jun-30, Volume: 565

    Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Hypersensitivity; Female; Glycerol; Ionic Liquids; Melanoma; Mice, Inbred C57BL; Paclitaxel; Skin Neoplasms

2019
miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy.
    Journal of experimental & clinical cancer research : CR, 2019, May-22, Volume: 38, Issue:1

    Topics: Aged; Animals; Apoptosis; Calcium-Binding Proteins; Carcinogenesis; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Membrane Proteins; Mice; MicroRNAs; Middle Aged; Paclitaxel; RNA-Binding Proteins; Xenograft Model Antitumor Assays

2019
Evaluating the Anti-cancer Efficacy of a Synthetic Curcumin Analog on Human Melanoma Cells and Its Interaction with Standard Chemotherapeutics.
    Molecules (Basel, Switzerland), 2019, Jul-06, Volume: 24, Issue:13

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Curcumin; Dose-Response Relationship, Drug; Drug Interactions; Humans; Melanoma; Mitochondria; Molecular Structure; Oxidative Stress; Paclitaxel; Tamoxifen

2019
Intravenous administration of manuka honey inhibits tumor growth and improves host survival when used in combination with chemotherapy in a melanoma mouse model.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Honey; Humans; Leptospermum; Male; Melanoma; Mice; Necrosis; Paclitaxel; Tumor Burden

2013
Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.
    Melanoma research, 2013, Volume: 23, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Salvage Therapy; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult

2013
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Female; Humans; Lymphatic Metastasis; Melanoma; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Temozolomide; Treatment Outcome; Vaginal Neoplasms; Vulvar Neoplasms

2013
BCL2 and BCLxL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells.
    Experimental dermatology, 2013, Volume: 22, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Biphenyl Compounds; Caspase 9; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Melanoma; Nitrophenols; Paclitaxel; Piperazines; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Spindle Apparatus; Sulfonamides; Tubulin

2013
[Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Melanoma; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tyrphostins

2013
Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Agents, Phytogenic; Calibration; Female; Humans; Mass Spectrometry; Melanoma; Mice; Mice, Nude; Nanoparticles; Paclitaxel

2013
Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2013, Volume: 67, Issue:8

    Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Caspases; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel

2013
Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response.
    Cancer letters, 2014, Feb-01, Volume: 343, Issue:1

    Topics: AC133 Antigen; Antigens, CD; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Transfer Techniques; Glycoproteins; Humans; Immunohistochemistry; Melanoma; Neoplasm Metastasis; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Peptides

2014
Multifunctional biodegradable polymer nanoparticles with uniform sizes: generation and in vitro anti-melanoma activity.
    Nanotechnology, 2013, Nov-15, Volume: 24, Issue:45

    Topics: Biocompatible Materials; Biodegradation, Environmental; Cell Death; Cell Line, Tumor; Cell Survival; Endocytosis; Humans; Inhibitory Concentration 50; Lactic Acid; Light; Magnetic Resonance Imaging; Magnetite Nanoparticles; Melanoma; Microscopy, Fluorescence; Paclitaxel; Particle Size; Phantoms, Imaging; Polyesters; Polymers; Polyvinyl Alcohol; Quantum Dots; Scattering, Radiation

2013
Overexpression of Heat Shock Transcription Factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel.
    BMC cancer, 2013, Oct-29, Volume: 13

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression; Gene Silencing; Heat Shock Transcription Factors; Humans; Inhibitory Concentration 50; Melanoma; Melanoma, Experimental; Mice; Mutation; Paclitaxel; Transcription Factors

2013
Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma.
    The Journal of dermatology, 2013, Volume: 40, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Skin Neoplasms; Treatment Failure

2013
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
    Pigment cell & melanoma research, 2014, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carboplatin; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Melanoma; Molecular Targeted Therapy; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Skin Neoplasms; Spheroids, Cellular; Tumor Stem Cell Assay

2014
Combination of Cl‑IB‑MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR‑dependent autophagy and mitotic catastrophe on human melanoma cells.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:6

    Topics: Adenosine; Adenosine A3 Receptor Agonists; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Blotting, Western; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Fluorescent Antibody Technique; Humans; Melanoma; Mitosis; Paclitaxel; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2014
Case of advanced melanoma who died from meningitis carcinomatosa after carboplatin and paclitaxel with good response.
    The Journal of dermatology, 2014, Volume: 41, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Melanoma; Meningeal Carcinomatosis; Middle Aged; Paclitaxel; Positron-Emission Tomography

2014
Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
    International journal of nanomedicine, 2014, Volume: 9

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Kaplan-Meier Estimate; Linoleic Acids, Conjugated; Liposomes; Melanoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Oligopeptides; Paclitaxel; Tissue Distribution; Xenograft Model Antitumor Assays

2014
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Adenosine; Animals; Antineoplastic Agents; Cell Physiological Phenomena; Disease Progression; Drug Screening Assays, Antitumor; Humans; Inosine; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Receptor, Adenosine A3; Tumor Cells, Cultured

2014
Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Lansoprazole; Melanoma; Mice; Mice, SCID; Paclitaxel; Proton Pump Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015
Non-occlusive mesenteric ischemia after chemotherapy for metastatic melanoma.
    The Journal of dermatology, 2015, Volume: 42, Issue:1

    Topics: Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Humans; Intestines; Ischemia; Melanoma; Paclitaxel; Splanchnic Circulation

2015
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
    Journal of translational medicine, 2015, Jan-27, Volume: 13

    Topics: Albumins; Apoptosis; Aurora Kinase B; Cell Line, Tumor; Cell Movement; Cell Nucleus Shape; Cell Proliferation; Cell Shape; Cell Survival; Drug Resistance, Neoplasm; Extracellular Space; Humans; Lactic Acid; Melanoma; Mitosis; Necrosis; Neoplasm Metastasis; Organophosphates; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines

2015
Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Melanoma; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins B-raf; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Vemurafenib

2015
Salvage chemotherapy with weekly paclitaxel for metastatic melanoma.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate

2015
c-Myc modulation: a key role in melanoma drug response.
    Cancer biology & therapy, 2015, Volume: 16, Issue:9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Humans; Hydrogen Peroxide; Melanoma; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Skin Neoplasms; Temozolomide

2015
Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Melanoma research, 2015, Volume: 25, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Managed Care Programs; Melanoma; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Retrospective Studies; Skin Neoplasms; Sulfonamides; Temozolomide; United States; Vemurafenib

2015
Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells.
    Theranostics, 2015, Volume: 5, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lipids; Melanoma; Mice; Nanoparticles; Neoplastic Stem Cells; Paclitaxel

2015
Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
    Molecular and cellular biochemistry, 2015, Volume: 406, Issue:1-2

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mitosis; Mutation, Missense; Paclitaxel; Proto-Oncogene Proteins B-raf; Sulfonamides; Transcriptional Activation

2015
Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy.
    International journal of nanomedicine, 2015, Volume: 10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Humans; Indoles; Melanoma; Nanoparticles; Paclitaxel; Polyesters; Polyethylene Glycols; Polymers; Surface Properties

2015
PEGylated graphene oxide for tumor-targeted delivery of paclitaxel.
    Nanomedicine (London, England), 2015, Volume: 10, Issue:8

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Graphite; Melanoma; Mice; Mice, Inbred C57BL; Oxides; Paclitaxel; Polyethylene Glycols; Rats, Wistar

2015
Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
    Drug delivery, 2016, Volume: 23, Issue:4

    Topics: Biological Transport; Cell Line, Tumor; Cell-Penetrating Peptides; Doxorubicin; Drug Delivery Systems; Humans; Ligands; Liposomes; Melanoma; Paclitaxel; Peptides; Transferrin; Xenograft Model Antitumor Assays

2016
In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.
    Pharmaceutical research, 2015, Volume: 32, Issue:9

    Topics: Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorescein-5-isothiocyanate; Humans; Integrin alphaVbeta3; Melanoma; Mice; Micelles; Microscopy, Confocal; Oligopeptides; Paclitaxel

2015
Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Albumins; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mutation, Missense; Paclitaxel; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib

2015
Is chemotherapy still an option in the treatment of melanoma?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:11

    Topics: Albumins; Dacarbazine; Female; Humans; Male; Melanoma; Paclitaxel; Skin Neoplasms

2015
Versatile antitumor potential of isoxanthohumol: Enhancement of paclitaxel activity in vivo.
    Pharmacological research, 2016, Volume: 105

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Flavonoids; Humans; MAP Kinase Signaling System; Melanoma; Mice, Inbred C57BL; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Xanthones

2016
Multiwalled Carbon Nanotubes Inhibit Tumor Progression in a Mouse Model.
    Advanced healthcare materials, 2016, Volume: 5, Issue:9

    Topics: Animals; Cell Line, Tumor; Drug Carriers; Melanoma; Mice; Nanotubes, Carbon; Neoplasms, Experimental; Paclitaxel

2016
Nanoparticle-dendrimer hybrid nanocapsules for therapeutic delivery.
    Nanomedicine (London, England), 2016, Volume: 11, Issue:12

    Topics: Animals; Antineoplastic Agents, Phytogenic; Arginine; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dendrimers; Female; Gold; Melanoma; Mice; Mice, Inbred C57BL; Nanocapsules; Nanoparticles; Paclitaxel; Thiocarbamates

2016
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:10

    Topics: Adult; Aged; Biomarkers, Pharmacological; Carboplatin; Cell-Free Nucleic Acids; DNA, Neoplasm; Exome Sequencing; Female; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Paclitaxel; Precision Medicine; Proto-Oncogene Proteins c-kit; Vaginal Neoplasms

2016
Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 83

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Survival; Endostatins; Female; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Recombinant Proteins; Xenograft Model Antitumor Assays

2016
A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor
    Theranostics, 2016, Volume: 6, Issue:12

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Galactosylceramides; Immunotherapy; Liposomes; Melanoma; Mice, Inbred C57BL; Nanostructures; Paclitaxel; Treatment Outcome

2016
Paclitaxel-induced aberrant mitosis and mitotic slippage efficiently lead to proliferative death irrespective of canonical apoptosis and p53.
    Cell cycle (Georgetown, Tex.), 2016, Volume: 15, Issue:23

    Topics: Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Clone Cells; Cysteine; DNA; Genes, Reporter; HeLa Cells; Humans; Kinesins; Melanoma; Mitochondrial Membranes; Mitosis; Paclitaxel; Permeability; Phenotype; Reproducibility of Results; Time-Lapse Imaging; Tumor Suppressor Protein p53

2016
Translocation of BBAP from the cytoplasm to the nucleus reduces the metastatic ability of vemurafenib-resistant SKMEL28 cells.
    Molecular medicine reports, 2017, Volume: 15, Issue:1

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Sulfonamides; Ubiquitin-Protein Ligases; Vemurafenib

2017
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Ipilimumab; Markov Chains; Melanoma; Models, Economic; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate

2017
Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Melanoma; Nanoparticles; Paclitaxel; Particle Size; Polymers; Structure-Activity Relationship; Surface Properties; Tumor Cells, Cultured

2017
Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.
    Hormones & cancer, 2017, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indoles; Melanoma; Multidrug Resistance-Associated Protein 2; Paclitaxel; Receptors, Somatotropin; Sulfonamides; Vemurafenib

2017
Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
    PloS one, 2008, Volume: 3, Issue:10

    Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Delivery Systems; Endocytosis; Glucose-6-Phosphate Isomerase; HCT116 Cells; HT29 Cells; Humans; Melanoma; Membrane Microdomains; Mice; Neoplasms; Paclitaxel; Receptors, Autocrine Motility Factor; Receptors, Cytokine; Ubiquitin-Protein Ligases

2008
Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
    Oncogene, 2009, Feb-19, Volume: 28, Issue:7

    Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ceramides; Humans; Lysophosphatidylcholines; Lysophospholipids; Melanoma; Membrane Potential, Mitochondrial; Multienzyme Complexes; Paclitaxel; Phosphodiesterase I; Phosphoric Diester Hydrolases; Pyrophosphatases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2009
Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells.
    The Journal of investigative dermatology, 2009, Volume: 129, Issue:6

    Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Chromatin; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Histones; Humans; Immunohistochemistry; Melanoma; Models, Biological; Paclitaxel; Tubulin

2009
Studies on paclitaxel-loaded glyceryl monostearate nanoparticles.
    Journal of microencapsulation, 2009, Volume: 26, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Glycerides; Lipids; Melanoma; Nanoparticles; Paclitaxel; Particle Size

2009
Efficacy of poly(sebacic acid-co-ricinoleic acid) biodegradable delivery system for intratumoral delivery of paclitaxel.
    Journal of biomedical materials research. Part A, 2010, Mar-15, Volume: 92, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Line; Decanoic Acids; Drug Carriers; Drug Delivery Systems; Female; Humans; Materials Testing; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Paclitaxel; Polymers; Ricinoleic Acids; Survival Rate

2010
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
    Cancer research, 2009, May-01, Volume: 69, Issue:9

    Topics: Adenosine Triphosphate; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluoresceins; Humans; Melanoma; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays

2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
    Journal of the American Academy of Dermatology, 2009, Volume: 60, Issue:5

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Delivery Systems; Female; Humans; Melanoma; Neoplasm Metastasis; Paclitaxel; Protein Kinases; Signal Transduction; Sirolimus; Skin Neoplasms; TOR Serine-Threonine Kinases

2009
MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.
    PloS one, 2009, Volume: 4, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Division; Cell Survival; DNA Replication; DNA, Neoplasm; Down-Regulation; G2 Phase; Humans; Melanoma; Mitosis; Paclitaxel; Proto-Oncogene Proteins c-myc; Spindle Apparatus; Tumor Cells, Cultured

2009
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Melanoma research, 2009, Volume: 19, Issue:3

    Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles

2009
Acute gout during treatment with paclitaxel for metastatic melanoma.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:7

    Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Gout; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms

2009
Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.
    Journal of drug targeting, 2011, Volume: 19, Issue:1

    Topics: Animals; Carbocyanines; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Endocytosis; Endothelial Cells; Flow Cytometry; Fluorescent Dyes; Humans; Integrins; Melanoma; Mice; Micelles; Microscopy, Confocal; Paclitaxel; Particle Size; Peptides, Cyclic; Polyethylene Glycols; Polyglactin 910

2011
Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
    PloS one, 2011, Feb-16, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Melanoma; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome; Young Adult

2011
Regression of paclitaxel-induced maculopathy with oral acetazolamide.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2012, Volume: 250, Issue:3

    Topics: Acetazolamide; Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbonic Anhydrase Inhibitors; Female; Humans; Lymphatic Metastasis; Macular Edema; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Tomography, Optical Coherence; Vision Disorders; Visual Acuity

2012
Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
    Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:2

    Topics: Animals; CD8-Positive T-Lymphocytes; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Immunosuppression Therapy; Inflammation; Melanoma; Mice; Mice, Knockout; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-ret; Purines; Receptors, Antigen, T-Cell; Sildenafil Citrate; Sulfones; Tumor Microenvironment; ZAP-70 Protein-Tyrosine Kinase

2012
Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1.
    Journal of translational medicine, 2012, Jan-10, Volume: 10

    Topics: Albumin-Bound Paclitaxel; Albumins; Animals; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Cytokines; Daunorubicin; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione; Humans; Isoxazoles; Melanoma; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Survival Analysis; Xenograft Model Antitumor Assays

2012
Anticancer and immunostimulatory activity by conjugate of paclitaxel and non-toxic derivative of LPS for combined chemo-immunotherapy.
    Pharmaceutical research, 2012, Volume: 29, Issue:8

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Immunotherapy; Lipopolysaccharides; Melanoma; Mice; Mice, Inbred C57BL; Paclitaxel

2012
Method to our madness or madness in our methods? Pitfalls in trial methodology.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-10, Volume: 30, Issue:17

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents

2012
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
    The Journal of investigative dermatology, 2012, Volume: 132, Issue:10

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Coloring Agents; Dacarbazine; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Interleukin-8; Melanoma; Mice; Mice, Nude; Paclitaxel; Side-Population Cells; Skin Neoplasms; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays

2012
Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2012, Volume: 50, Issue:9

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flavonoids; Flow Cytometry; Humans; Interleukin-8; Melanoma; Paclitaxel; Signal Transduction; Toll-Like Receptor 4; Vascular Endothelial Growth Factor A

2012
Fatty acid-RGD peptide amphiphile micelles as potential paclitaxel delivery carriers to α(v)β₃ integrin overexpressing tumors.
    Pharmaceutical research, 2012, Volume: 29, Issue:12

    Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fatty Acids; Humans; Integrin alphaVbeta3; Melanoma; Micelles; Oligopeptides; Paclitaxel; Surface-Active Agents

2012
Croton lechleri sap and isolated alkaloid taspine exhibit inhibition against human melanoma SK23 and colon cancer HT29 cell lines.
    Journal of ethnopharmacology, 2012, Dec-18, Volume: 144, Issue:3

    Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Croton; HT29 Cells; Humans; Melanoma; Paclitaxel; Plant Extracts; Vinblastine

2012
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
    Journal of immunology (Baltimore, Md. : 1950), 2013, Mar-01, Volume: 190, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Calgranulin B; Chronic Disease; Dose-Response Relationship, Immunologic; Humans; Immunosuppression Therapy; Inflammation; Melanoma; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinases; Myeloid Cells; Paclitaxel; Primary Cell Culture; Skin Neoplasms; Spleen; Tumor Microenvironment; Tumor Necrosis Factor-alpha

2013
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
    Cancer letters, 2002, Dec-05, Volume: 186, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Fluorescent Antibody Technique, Indirect; Humans; Immunophenotyping; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Melanoma; Microscopy, Electron; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Temozolomide; Time Factors; Tumor Cells, Cultured; Vindesine

2002
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
    International journal of cancer, 2003, Mar-10, Volume: 104, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Capillaries; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Division; Cells, Cultured; Chemotaxis; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelium, Vascular; Fibrosarcoma; Glioblastoma; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays

2003
Tumor growth retardation, cure, and induction of antitumor immunity in B16 melanoma-bearing mice by low electric field-enhanced chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bleomycin; Cell Division; Cisplatin; Combined Modality Therapy; Electric Stimulation Therapy; Macrophages; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Spleen; T-Lymphocytes; Time Factors

2003
Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor.
    Cancer research, 2003, Aug-15, Volume: 63, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Chemokine CXCL1; Chemokines; Chemokines, CXC; Chemotactic Factors; Dactinomycin; Enzyme Inhibitors; Female; Gene Expression Profiling; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Melanoma; Mitogen-Activated Protein Kinase Kinases; Nitriles; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel

2003
Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine.
    Biochemical pharmacology, 2003, Sep-01, Volume: 66, Issue:5

    Topics: Antineoplastic Agents; Cell Cycle; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Keratinocytes; Melanoma; Paclitaxel; Purinergic P1 Receptor Antagonists; Pyrimidines; Receptor, Adenosine A3; Triazoles; Tumor Cells, Cultured; Vindesine

2003
Angiogenesis gene expression profiling in xenograft models to study cellular interactions.
    Experimental cell research, 2004, Oct-01, Volume: 299, Issue:2

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Base Sequence; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Molecular Sequence Data; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin Neoplasms; Transplantation, Heterologous

2004
Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel.
    Journal of mathematical biology, 2004, Volume: 49, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Flow Cytometry; Humans; Mathematics; Melanoma; Models, Biological; Paclitaxel

2004
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
    Anti-cancer drugs, 2005, Volume: 16, Issue:9

    Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid

2005
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.
    Cancer, 2006, Jan-15, Volume: 106, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome

2006
Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging.
    Cancer biology & therapy, 2006, Volume: 5, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Capsules; Contrast Media; Cricetinae; Gadolinium DTPA; Lipids; Magnetic Resonance Imaging; Melanoma; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured

2006
[A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Humans; Kidney Neoplasms; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Melanoma; Paclitaxel; Quality of Life

2006
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand.
    Biochemistry, 2006, Aug-08, Volume: 45, Issue:31

    Topics: Amino Acid Sequence; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Ligands; Melanoma; Molecular Chaperones; Molecular Sequence Data; Paclitaxel; Peptide Library; Peptides, Cyclic; Protein Transport

2006
Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
    International journal of oncology, 2006, Volume: 29, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Breast Neoplasms; Cell Growth Processes; Chick Embryo; Collagen Type IV; Dose-Response Relationship, Immunologic; Drug Synergism; Epitopes; Extracellular Matrix; Female; Humans; Immunoglobulin G; Immunoglobulin M; Male; Melanoma; Mice; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1

2006
Therapeutic effects of paclitaxel-containing ultrasound contrast agents.
    Ultrasound in medicine & biology, 2006, Volume: 32, Issue:11

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Death; Chick Embryo; Chorioallantoic Membrane; Contrast Media; Drug Carriers; Drug Delivery Systems; Humans; Integrin alphaVbeta3; Ligands; Melanoma; Microbubbles; Neoplasm Proteins; Paclitaxel; Sonication; Tumor Cells, Cultured

2006
Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:2

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Paclitaxel; Remission Induction; Skin Neoplasms

2007
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2007, Volume: 30, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; Combined Modality Therapy; HMGB1 Protein; Humans; Immunotherapy; Killer Cells, Lymphokine-Activated; Melanoma; Melphalan; Microscopy, Confocal; Necrosis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms

2007
Dominant negative Rac1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27: a functional proteomic analysis.
    Proteomics, 2007, Volume: 7, Issue:22

    Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Electrophoresis, Gel, Two-Dimensional; Genes, Dominant; Heat-Shock Proteins; Humans; Melanoma; Mitochondria; Paclitaxel; Peptides; Proteomics; rac1 GTP-Binding Protein; Sensitivity and Specificity; Tumor Cells, Cultured; Up-Regulation

2007
Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2.
    Cellular signalling, 2008, Volume: 20, Issue:2

    Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Down-Regulation; Enzyme Activation; Free Radical Scavengers; Humans; Ion Channels; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; MAP Kinase Signaling System; Melanoma; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Proteins; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Reactive Oxygen Species; Uncoupling Protein 2

2008
Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Journal of the National Cancer Institute, 2008, Jan-02, Volume: 100, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Hydrazines; Melanoma; Paclitaxel; Randomized Controlled Trials as Topic; Reactive Oxygen Species; Research Design; Skin Neoplasms

2008
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
    Investigational new drugs, 1995, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Docetaxel; Drugs, Investigational; Female; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids; Transplantation, Heterologous

1995
Metastasis-associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma.
    DNA and cell biology, 1994, Volume: 13, Issue:4

    Topics: Calcium-Binding Proteins; Cell Cycle; Gene Expression; Melanocyte-Stimulating Hormones; Melanoma; Neoplasm Metastasis; Paclitaxel; S100 Proteins; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1994
Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases.
    Cancer, 1995, Jul-01, Volume: 76, Issue:1

    Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Docetaxel; Edema; Female; Humans; Leg; Leiomyosarcoma; Lung Neoplasms; Male; Melanoma; Middle Aged; Paclitaxel; Scleroderma, Localized; Taxoids

1995
The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma.
    Anti-cancer drugs, 1996, Volume: 7, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Drug Screening Assays, Antitumor; Humans; Melanoma; Paclitaxel; Tumor Cells, Cultured

1996
Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug.
    Anti-cancer drugs, 1996, Volume: 7, Issue:6

    Topics: Animals; Drug Screening Assays, Antitumor; Female; Mammary Neoplasms, Experimental; Melanoma; Mice; Paclitaxel; Polyethylene Glycols; Prodrugs; Tumor Cells, Cultured

1996
In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Fluorescent Antibody Technique, Indirect; Humans; Melanoma; Microscopy, Electron; Paclitaxel; Tubulin; Tumor Cells, Cultured; Vinblastine; Vinorelbine

1997
Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:3

    Topics: Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lung Neoplasms; Melanoma; Paclitaxel; Radiation-Sensitizing Agents; Tumor Cells, Cultured

1997
Differential effects of taxol on two human cancer cell lines.
    Oncology research, 1997, Volume: 9, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescent Antibody Technique, Indirect; HT29 Cells; Humans; Melanoma; Microtubules; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured

1997
Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays.
    Cancer chemotherapy and pharmacology, 1997, Volume: 41, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Assay; Cattle; Cells, Cultured; Dimethyl Sulfoxide; Docetaxel; Drug Screening Assays, Antitumor; In Vitro Techniques; Melanoma; Mice; Microtubule-Associated Proteins; Mitosis; Paclitaxel; Taxoids

1997
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
    British journal of cancer, 1999, Volume: 79, Issue:9-10

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay

1999
Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9

    Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Dog Diseases; Dogs; Doxorubicin; Female; Lung Neoplasms; Male; Melanoma; Paclitaxel; Sarcoma

1999
Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications.
    Oncogene, 2000, Jan-20, Volume: 19, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Cisplatin; Humans; Intramolecular Oxidoreductases; Melanoma; Methotrexate; Paclitaxel; Tumor Cells, Cultured

2000
Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.
    Pharmaceutical research, 2000, Volume: 17, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Emulsions; Female; Filtration; Humans; Melanoma; Mice; Mice, Inbred Strains; Paclitaxel; Particle Size; Serum Albumin; Skin Neoplasms; Solubility; Sterilization; Survival Analysis; Vitamin E

2000
Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 297, Issue:3

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytoprotection; Electrophoresis, Polyacrylamide Gel; Fibroblasts; HeLa Cells; Humans; Melanoma; Mercaptoethylamines; Mice; NF-kappa B; NF-kappa B p50 Subunit; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Proto-Oncogene Proteins c-mdm2; Transcription Factor AP-1; Transcription Factors; Transcriptional Activation; Tumor Suppressor Protein p53

2001
Chemotherapy of metastatic melanoma.
    The Mount Sinai journal of medicine, New York, 1992, Volume: 59, Issue:3

    Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Humans; Melanoma; Mitolactol; Paclitaxel

1992
New approaches to the chemotherapy of melanoma.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine

1991
A phase II trial of taxol in metastatic melanoma.
    Cancer, 1990, Jun-01, Volume: 65, Issue:11

    Topics: Adult; Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel

1990
Hypersensitivity reactions from taxol.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:7

    Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Colonic Neoplasms; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Immediate; Leukemia, Myeloid, Acute; Male; Melanoma; Middle Aged; Paclitaxel; Premedication

1990
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Humans; Infusions, Intravenous; Kinetics; Melanoma; Neoplasms; Nervous System Diseases; Neutropenia; Paclitaxel

1987
6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 51, Issue:2

    Topics: Acetylation; Apoptosis; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavanones; Flavonoids; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Humulus; Melanoma; Molecular Docking Simulation; Protein Isoforms; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases

2018